BLS Pharmaceuticals Limited (ASX:BLS)
Australia · Delayed Price · Currency is AUD 1.180
-0.025 (-2.07%)
Sep 22, 2026, 4:10 PM AEST
BLS Pharmaceuticals Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Operating Revenue | 74.16 | 28.43 | 9.33 | 5.15 | 0.46 |
Other Revenue | -0.25 | 0.85 | 0.32 | 0.14 | - |
| 73.91 | 29.28 | 9.64 | 5.3 | 0.46 | |
Revenue Growth | 152.42% | 203.66% | 81.97% | 1042.88% | -78.97% |
Cost of Revenue | 34.43 | 12.25 | 5.93 | 3.73 | 0.33 |
Gross Profit | 39.48 | 17.03 | 3.72 | 1.57 | 0.13 |
Selling, General & Admin | 16.33 | 7.33 | 3.64 | 2.69 | 0.49 |
Research & Development | - | - | 0.72 | - | - |
Operating Expenses | 19.93 | 9.31 | 4.85 | 3.38 | 0.59 |
Operating Income | 19.55 | 7.72 | -1.13 | -1.82 | -0.45 |
Interest Expense | -0.46 | -0.13 | - | - | - |
Interest & Investment Income | 0.07 | 0.02 | 0.02 | 0 | - |
Currency Exchange Gain (Loss) | - | - | - | 0.04 | 0 |
Other Non Operating Income (Expenses) | -4 | -2.71 | -0.21 | -0.04 | -0 |
EBT Excluding Unusual Items | 15.16 | 4.9 | -1.32 | -1.82 | -0.45 |
Impairment of Goodwill | - | - | -11.57 | - | - |
Gain (Loss) on Sale of Assets | - | - | -0.08 | - | - |
Asset Writedown | - | - | - | -0.1 | -0.04 |
Pretax Income | 15.16 | 4.9 | -12.97 | -1.92 | -0.49 |
Income Tax Expense | -0.24 | - | - | - | - |
Earnings From Continuing Operations | 15.4 | 4.9 | -12.97 | -1.92 | -0.49 |
Earnings From Discontinued Operations | - | - | -0.53 | -0.05 | - |
Net Income to Company | 15.4 | 4.9 | -13.5 | -1.96 | -0.49 |
Minority Interest in Earnings | - | - | 0.18 | 0.02 | - |
Net Income | 15.4 | 4.9 | -13.33 | -1.94 | -0.49 |
Net Income to Common | 15.4 | 4.9 | -13.33 | -1.94 | -0.49 |
Net Income Growth | 214.15% | - | - | - | - |
Shares Outstanding (Basic) | 222 | 208 | 193 | 134 | 73 |
Shares Outstanding (Diluted) | 230 | 215 | 193 | 134 | 73 |
Shares Change | 6.91% | 11.36% | 43.61% | 83.52% | 14.42% |
EPS (Basic) | 0.07 | 0.02 | -0.07 | -0.01 | -0.01 |
EPS (Diluted) | 0.07 | 0.02 | -0.07 | -0.01 | -0.01 |
EPS Growth | 191.30% | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | 1.61 | 4.21 | -3.74 | -1.19 | -0.57 |
Free Cash Flow Per Share | 0.01 | 0.02 | -0.02 | -0.01 | -0.01 |
Gross Margin | 53.42% | 58.17% | 38.53% | 29.55% | 29.10% |
Operating Margin | 26.45% | 26.36% | -11.75% | -34.32% | -97.72% |
Profit Margin | 20.83% | 16.74% | -138.19% | -36.61% | -106.55% |
Free Cash Flow Margin | 2.17% | 14.37% | -38.77% | -22.45% | -122.27% |
EBITDA | 20.13 | 8.02 | -1.08 | -1.71 | -0.42 |
EBITDA Margin | 27.23% | 27.40% | -11.22% | -32.25% | -91.09% |
D&A For EBITDA | 0.58 | 0.3 | 0.05 | 0.11 | 0.03 |
EBIT | 19.55 | 7.72 | -1.13 | -1.82 | -0.45 |
EBIT Margin | 26.45% | 26.36% | -11.75% | -34.32% | -97.72% |